Eligibility and communication
Eligibility, invitation, shared decision-making, smoking cessation support, consent, and risk communication.
Purpose of this page
This page explains how to interpret lung cancer screening risk estimates, thresholds, pulmonary nodules, and incidental findings without mistaking them for a diagnosis.
Many people understand that screening can find cancer earlier. Fewer understand that a safe programme also needs capacity for many normal scans, benign nodules, recall scans, PET/CT, biopsy, MDT review, surgery for selected cases, and findings outside the lung nodule pathway.
This page is intended for education, programme planning, and shared understanding. It does not determine whether an individual should be screened or how a CT finding should be managed.
Clinical disclaimer: This page explains population risk, screening thresholds, nodule management, and incidental findings for education and programme planning. It does not replace national guidelines, local protocols, multidisciplinary team assessment, clinical judgement, or patient preference.
Key message
Risk is not the same as diagnosis
A 6-year lung cancer risk estimate describes the expected number of future lung cancers in a group of similar people. It does not say that a specific person currently has cancer.
Example
A 1.5% 6-year risk means about 1 to 2 people out of 100 with similar risk factors may develop lung cancer over 6 years, while about 98 to 99 may not.
Example threshold
1.51%
PLCOm2012 risk over 6 years.
This is a screening selection threshold, not a diagnostic statement.
What does a 1.5% 6-year risk mean?
Imagine 100 people with similar age, smoking history, BMI, COPD, family history, and other model variables. Around 1 to 2 may develop lung cancer over 6 years. The model does not identify exactly which person this will be.
Why screening thresholds exist
Screening thresholds balance benefit and harm. If the threshold is too low, many low-risk people may receive scans with little chance of benefit. If the threshold is too high, some people who could benefit may be missed.
| Threshold choice | Effect | Programme consequence |
|---|---|---|
| Lower threshold | More people eligible. More cancers may be found. | More scans, more nodules, more incidental findings, more follow-up. |
| Higher threshold | Fewer people eligible. Screening is focused on higher-risk groups. | Fewer scans and downstream investigations, but some cancers may be missed. |
Population selection: A threshold such as PLCOm2012 risk at or above 1.51% over 6 years means that the person belongs to a risk group where screening may be justified under a defined programme rule. It does not mean cancer is likely now.
The evidence base for screening
Low-dose CT screening reduces lung cancer mortality in high-risk people. Two large randomised trials anchor the evidence, and eligibility criteria define who is offered screening.
| Source | What it established |
|---|---|
| NLST (2011) | First large randomised trial: annual low-dose CT reduced lung cancer mortality by about 20% compared with chest X-ray in high-risk smokers. |
| NELSON (2020) | European randomised trial using volume-based nodule management; confirmed a lung cancer mortality reduction (about 24% in men at 10 years). |
| USPSTF 2021 | Eligibility criterion in wide use: age 50–80, at least 20 pack-years, current smoker or quit within 15 years. Expanded from the 2013 criteria (age 55–74, at least 30 pack-years). |
| EU Council Recommendation (2022) | Extended the recommended cancer screening programmes to include lung cancer (low-dose CT) for heavy smokers — directly relevant to Nordic implementation. |
Two ways to select people: programmes use either categorical criteria (for example USPSTF 2021 age and pack-year cut-offs) or a risk model (for example PLCOm2012 at or above 1.51% over 6 years). The two approaches select overlapping but not identical groups. The NTOG LungRisk hub lets you compare them for the same person.
Smoking cessation is part of screening. A screening visit is a teachable moment. Integrated smoking cessation support increases the net benefit of a programme and is considered a core component of modern lung cancer screening, not an optional add-on.
Nordic and European trials (for example DLCST in Denmark, MILD, LUSI, UKLS) and ongoing studies (4-IN-THE-LUNG-RUN, SOLACE) continue to refine eligibility, screening interval, and nodule management. National Nordic screening programmes are at different stages of implementation; this page is educational and not a national recommendation.
Screening is a pathway, not a single scan
A safe screening programme needs a complete pathway for risk selection, CT acquisition, nodule measurement, recall scans, incidental findings, PET/CT, biopsy, surgery, MDT review, and audit.
Operational point: Screening capacity is not only scanner capacity. It also requires radiology time, tracking systems, recall governance, diagnostic capacity, MDT capacity, treatment capacity, communication processes, and quality assurance.
Imaging and reporting
Low-dose CT protocol, structured reporting, nodule measurement, previous imaging comparison, and incidental finding classification.
Follow-up and audit
Surveillance intervals, recall systems, PET/CT, biopsy, MDT review, treatment, communication, and outcomes audit.
Why pulmonary nodules need structured management
Small lung nodules are common on CT. Most are benign, especially very small nodules.
The purpose of nodule management systems is to identify the minority that need closer assessment while avoiding unnecessary procedures for benign findings.
Nodule size, growth, density, morphology, location, patient risk factors, and previous imaging all affect interpretation.
Important: Finding a nodule does not mean finding cancer. Structured nodule pathways reduce avoidable anxiety, unnecessary imaging, and unnecessary procedures.
Incidental findings are part of screening
CT screening can show findings outside the target question of lung cancer. These findings need programme rules before screening starts.
Incidental findings may include emphysema, coronary artery calcification, interstitial lung abnormalities, adrenal lesions, thyroid nodules, kidney lesions, liver lesions, aortic aneurysm, or other abnormalities.
Programmes need agreed rules for which findings are reported, which require follow-up, which can be ignored, and how results are communicated.
Safe programmes avoid unmanaged diagnostic cascades
A screening programme can become inefficient if every small or low-risk finding leads to additional imaging, referrals, or procedures.
Structured thresholds and nodule-management systems reduce unnecessary follow-up while preserving safety. The aim is not to ignore findings. The aim is to manage findings proportionately.
- False-positive and overdiagnosis communication
- Recall governance and nodule tracking
- Incidental finding policy
- MDT, biopsy, surgical, and oncology capacity
- Equity monitoring, quality assurance, and outcomes audit
What a screening programme must be able to handle
A good programme is not just buying CT scanners and inviting people. It needs the full pathway.
Many scans
Most screened people will not have lung cancer, but their scans still require acquisition, reporting, communication, and audit.
Many benign nodules
Small nodules are frequent. Most do not need invasive procedures, but they need structured interpretation.
Repeat surveillance
Some findings require repeat CT at defined intervals. Reliable recall systems are essential.
Selected escalation
PET/CT, biopsy, MDT review, surgery, radiotherapy, or systemic therapy may be needed for selected cases.
Incidental findings
Findings outside the lung nodule pathway need explicit, proportionate, auditable policy.
Clear rules
Rules reduce anxiety, unnecessary follow-up, variation, and unmanaged diagnostic cascades.